Drug
ADS-5102
ADS-5102 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_3
3
75%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 33 (75.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
Open-Label Safety Study of ADS-5102 in PD Patients With LID
NCT02202551
completedphase_3
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
NCT02136914
completedphase_3
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
NCT02274766
completedphase_2
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
NCT02471222
Clinical Trials (4)
Showing 4 of 4 trials
NCT02202551Phase 3
Open-Label Safety Study of ADS-5102 in PD Patients With LID
NCT02136914Phase 3
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
NCT02274766Phase 3
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
NCT02471222Phase 2
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4